Use of microminipigs for unveiling unknown mechanisms of azithromycin-induced cardiovascular death

• Main Authors: Ai Goto, Mihoko Hagiwara-Nagasawa, Hiroko Izumi-Nakaseko, Kumiko Kitta, Kiyotaka Hoshiai, Koki Chiba, Kentaro Ando, Yasuki Akie, Atsuhiko T. Naito, Atsushi Sugiyama
• Format: Article
• Language: English
• Published: Elsevier 2018-11-01
• Series: Journal of Pharmacological Sciences
• Online Access: http://www.sciencedirect.com/science/article/pii/S1347861318301877

Although azithromycin can suppress cardiac INa, IKr, IKs, ICa,L and IK1, its onset mechanisms for cardiovascular death have not been fully investigated. We examined electropharmacological effects of azithromycin in intravenous doses of 0.3, 3 and 30 mg/kg using microminipigs under the halothane anesthesia (n = 4), which provided plasma concentrations of 3.1, 11.2 and 120.4 μg/mL, respectively. The low dose did not alter any of the cardiohemodynamic or electrocardiographic variables. The middle dose significantly shortened QT interval for 10–20 min and QTc for 10–30 min. The high dose significantly decreased mean blood pressure for 5–60 min, prolonged QRS width at 20 min, but shortened QT interval for 15–20 min and QTc for 15–30 min (n = 3). Cardiohemodynamic collapse occurred in 1 animal after the start of the high dose infusion, which might be associated with the cardiovascular death in patients with vasomotor dysfunction. Prolongation of QRS width indicates that azithromycin may suppress ventricular INa in vivo, which may unmask latent type of Brugada electrocardiographic genotype. Meanwhile, abbreviation of the QTc might cause potentially lethal, short QT-related, cardiac arrhythmia syndrome. These findings with microminipigs suggest the possible entry point for analyzing the mechanisms of cardiovascular death clinically seen with this antibiotic. Keywords: Azithromycin, Microminipigs, Short QT syndrome, Brugada syndrome, Hypotension